Ketogenic diets are high in fat, moderate in protein and low in carbohydrates, with weak to preliminary evidence of anticancer effects, relief of side effects, and benefits on your body terrainthe internal conditions of your body, including nutritional status, fitness, blood sugar balance, hormone balance, inflammation and more.

Are you a health professional?

This section does not replicate the other information on this topic but provides additional details or context most relevant to professionals.

Modes of action: metabolism

Inducing ketosis: countering the Warburg effect

Some cancer cells within tumors, as well as tumor-associated cells (such as fibroblasts and macrophages) undergo metabolic changes in response to hypoxia (low oxygen and oxidative stress) of the tumor microenvironment.1Martinez-Outschoorn U, Sotgia F, Lisanti MP. Tumor microenvironment and metabolic synergy in breast cancers: critical importance of mitochondrial fuels and function. Seminars in Oncology. 2014 Apr;41(2):195-216.

A key alteration of these cells is converting to a complete dependence on glucose for energy generation. These catabolic cells do not have intact mitochondria, and so normal energy production via citric acid cycling and oxidative phosphorylation is not available.

Cells with intact mitochondria can use various metabolic substrates including glucose, fatty acids, glutamine and even ketones to fuel energy production. Catabolic cancer cells and tumor associated stromal cells, on the other hand, lose the ability to make ATP in the mitochondria and instead rely solely upon metabolizing glucose via glycolysis in the cytoplasm to generate ATP.2Schroeder U, Himpe B et al. Decline of lactate in tumor tissue after ketogenic diet: in vivo microdialysis study in patients with head and neck cancer. Nutrition and Cancer. 2013;65(6):843-9. This is called the Warburg effect and is a known attribute of the tumor microenvironment. 

Typical Western diets high in refined carbohydrates provide this glucose substrate as well as promote the insulin pathway, releasing growth factors that are associated with promoting cancer development and progression.3Erickson N, Boscheri A, Linke B, Huebner J. Systematic review: isocaloric ketogenic dietary regimes for cancer patients. Medical Oncology. 2017 May;34(5):72. A ketogenic diet, which severely limits the supply of glucose in favor of ketones, is thought to selectively starve these tumor cells. Evidence suggests that some cancer cells appear less able to metabolize ketones compared with healthy cells.4Liberti MV, Locasale JW. The Warburg effect: how does it benefit cancer cells? Trends in Biochemical Sciences. 2016;41(3):211-218; Zhao L, Mao Y, Zhao Y, Cao Y, Chen X. Role of multifaceted regulators in cancer glucose metabolism and their clinical significance. Oncotarget. 2016;7(21):31572-31585; Martinez-Outschoorn UE, Lin Z, Whitaker-Menezes D, Howell A, Sotgia F, Lisanti MP. Ketone body utilization drives tumor growth and metastasis. Cell Cycle. 2012 Nov 1; 11(21): 3964–3971; Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. Journal of General Physiology. 1927;8(6):519-530. 

Of note, while both caloric restriction and a ketogenic diet lower blood glucose and insulin levels, only calorie restriction also lowers fatty acids, and fatty acids may be an important part of anticancer action with some tumors. A mouse study found that only caloric restriction inhibited the growth of select pancreatic tumor allografts in mice. A ketogenic diet alone did not. Further, a higher-fat caloric-restriction diet conferred resistance to the effects of caloric restriction. Altering the fat composition of a ketogenic diet to increase levels of saturated fatty acids in tumors decreased tumor stearoyl-CoA desaturase (SCD) activity to slow tumor growth.5Lien EC, Westermark AM et al. Low glycaemic diets alter lipid metabolism to influence tumour growth. Nature. 2021 Nov;599(7884):302-307.

The impact of ketosis on cancer cells does not rely solely on the Warburg effect. The effects of ketosis may induce oxidative stress specific to cancer cells, which may potentiate the effect of chemotherapy and radiation.6Zick SM, Snyder D, Abrams DI. Pros and cons of dietary strategies popular among cancer patients. Oncology (Williston Park). 2018 Nov 15;32(11):542-7. 

Reverse Warburg effect: cancer cells adapt

Researchers have proposed the reverse Warburg effect. As tumor-associated cells such as fibroblasts and immune cells struggle under the highly oxidative tumor environment, these cells lose the ability to retain oxidative phosphorylation and, instead, revert to glycolysis for energy production and start to undergo autophagy, a process of self-digestion. The glycolysis and autophagy generate many energy-rich substrates such as fatty acids, lactate, and ketones which these tumor-associated cells release. These substrates are then taken up by growing (anabolic) cancer cells as fuel. 

Experiments show that some tumor cells are able to use lactate and ketones for energy.7Schroeder U, Himpe B et al. Decline of lactate in tumor tissue after ketogenic diet: in vivo microdialysis study in patients with head and neck cancer. Nutrition and Cancer. 2013;65(6):843-9; Martinez-Outschoorn UE, Lisanti MP, Sotgia F. Catabolic cancer-associated fibroblasts transfer energy and biomass to anabolic cancer cells, fueling tumor growth. Seminars in Cancer Biology. 2014 Apr;25:47-60; Martinez-Outschoorn UE, Lin Z et al. Ketone body utilization drives tumor growth and metastasis. Cell Cycle. 2012 Nov 1;11(21):3964-71; Maurer GD, Brucker DP et al. Differential utilization of ketone bodies by neurons and glioma cell lines: a rationale for ketogenic diet as experimental glioma therapy. BMC Cancer. 2011 Jul 26;11:315; Seyfried TN, Sanderson TM, El-Abbadi MM, McGowan R, Mukherjee P. Role of glucose and ketone bodies in the metabolic control of experimental brain cancer. British Journal of Cancer 2003;89:1375–82. In this way, tumor-associated cells essentially feed growing cancer cells, the reverse Warburg effect.8Bonuccelli G, Tsirigos A et al. Ketones and lactate can actually “fuel” tumor growth, angiogenesis and metastasis: evidence that epithelial cancer cells use oxidative mitochondrial metabolism. Cell Cycle 2010;9:3506–14; Martinez-Outschoorn UE, Prisco M et al. Ketones and lactate increase cancer cell “stemness”, driving recurrence, metastasis and poor clinical outcome in breast cancer: achieving personalized medicine via metabolo-genomics. Cell Cycle 2011;10:1271–86. “In vitro data showed that cancer cells not only adapt to the situation but develop mutations and characteristics of stem cells. One hypothesis is that the [ketogenic] diet puts the tumor under stress and thus selects for resistance and malignancy. In an experiment on mice, the tumors in the diet-treated group initially grew less but later tumor growth accelerated and exceeded that of the control group.”9Huebner J, Marienfeld S et al. Counseling patients on cancer diets: a review of the literature and recommendations for clinical practice. Anticancer Research 2014;34:39–48.

Researchers propose that the Warburg and reverse Warburg effects are not totally competitive, but rather reflect the ability of cancer cells to use different metabolic substrates depending upon what is available and what mutations are present.10Yaojie Fu, Shanshan Liu et al. The reverse Warburg effect is likely to be an Achilles’ heel of cancer that can be exploited for cancer therapy. Oncotarget. 2017 Aug 22; 8(34): 57813–57825; Branco AF, Ferreira A et al. Ketogenic diets: from cancer to mitochondrial diseases and beyond. European Journal of Clinical Investigation. 2016 Mar;46(3):285-98.

The glycolytic pattern is not the only way cancer metabolizes glucose, and therapeutics including the ketogenic diet targeting glycolysis in cancer patients have not always had positive responses.11Yaojie Fu, Shanshan Liu et al. The reverse Warburg effect is likely to be an Achilles’ heel of cancer that can be exploited for cancer therapy. Oncotarget. 2017 Aug 22; 8(34): 57813–57825.

Lower risk of cachexia

Ketogenic diets may have a protein-sparing effect that preserves lean body mass, reducing the risk or severity of cancer cachexia.12Zick SM, Snyder D, Abrams DI. Pros and cons of dietary strategies popular among cancer patients. Oncology (Williston Park). 2018 Nov 15;32(11):542-7.

Further evidence 

Notable preclinical evidence; clinical evidence is summarized in How can a ketogenic diet help me? What the research shows ›

Improving treatment outcomes: preclinical evidence

Advanced cancer

  • Prolonged survival among mice with metastatic cancer treated with a KD combined with hyperbaric oxygen compared to using either therapy alone13Poff AM, Ari C, Seyfried TN, D’Agostino DP. The ketogenic diet and hyperbaric oxygen therapy prolong survival in mice with systemic metastatic cancer. PLoS One. 2013 Jun 5;8(6):e65522.

Brain cancer

Breast cancer (mammary cancer)

  • Slower mammary tumor growth and increased tumor latency in mice fed a KD,18Gluschnaider U, Hertz R et al. Long-chain fatty acid analogues suppress breast tumorigenesis and progression. Cancer Research. 2014 Dec 1;74(23):6991-7002. and this effect was increased when mice were also treated with metformin19Zhuang Y, Chan DK, Haugrud AB, Miskimins WK. Mechanisms by which low glucose enhances the cytotoxicity of metformin to cancer cells both in vitro and in vivo. PLoS One. 2014 Sep 25;9(9):e108444.

Colon cancer

  • Reduced tumor weight among animals transplanted with MAC16 colon adenocarcinoma fed a KD20Beck SA, Tisdale MJ. Nitrogen excretion in cancer cachexia and its modification by a high fat diet in mice. Cancer Research. 1989 Jul 15;49:3800–4.

Gastrointestinal cancer

Lung cancer

  • Slower tumor growth among lung cancer xenograft mice treated with KD and radiation compared to radiation alone (assuming a standard diet), or when KD was used with carboplatin and radiation compared to controls22Allen BG, Bhatia SK et al. Ketogenic diets enhance oxidative stress and radio-chemo-therapy responses in lung cancer xenografts. Clinical Cancer Research. 2013 Jul 15;19(14):3905-13.

Pancreatic cancer

  • Higher tumor NADH and less tumor growth, tripling the survival benefits of chemotherapy alone, in mice fed a ketogenic diet added to chemotherapy; chemotherapy and ketogenic diet also synergize in immune-deficient mice, although long-term growth suppression was only observed in mice with an intact immune system23Yang L, TeSlaa T et al. Ketogenic diet and chemotherapy combine to disrupt pancreatic cancer metabolism and growth. Med. 2022;3(2):119-136.e8.

Prostate cancer

Insufficient (preclinical) evidence of slower tumor growth and improved survival, and little difference in effect with 0% compared to 20% carbohydrate in the diet

  • Reduced prostate tumor growth and prolonged survival among mice with an unrestricted no-carbohydrate ketogenic diet compared to Western diet24Freedland SJ, Mavropoulos J et al. Carbohydrate restriction, prostate cancer growth, and the insulin-like growth factor axis. Prostate. 2008 Jan 1;68:11–9. 
  • Prolonged survival among prostate cancer xenograft mice with a no-carbohydrate ketogenic diet compared to either a low-fat/high-carbohydrate diet or a high-fat/moderate-carbohydrate diet, in amounts to maintain similar body weights across groups25Mavropoulos JC, Buschemeyer WC et al. The effects of varying dietary carbohydrate and fat content on survival in a murine LNCaP prostate cancer xenograft model. Cancer Prevention Research (Philadelphia, Pennsylvania). 2009 Jun;2:557–65.
  • No slowing of adenocarcinoma development among prostate cancer xenograft mice with an unrestricted no-carbohydrate ketogenic diet compared to an unrestricted Western diet26Allott EH, Macias E et al. Impact of carbohydrate restriction in the context of obesity on prostate tumor growth in the Hi-Myc transgenic mouse model. Prostate Cancer and Prostatic Diseases. 2017 Jun;20(2):165-171. Note: the mice in this study on the ketogenic diet had higher body weights at 6 months, and the authors conclude that “although carbohydrate restriction within the context of obesity may reduce obesity-associated systemic inflammation, it is not sufficient to counteract obesity-associated tumor growth.” Calorie restriction with KD may be important.
  • Slower prostate cancer tumor growth among castrated mice with a 20% carbohydrate diet (calorie-controlled relative to the Western diet) compared to an unrestricted Western diet, and similar to 0% and 10% carbohydrate diets27Caso J, Masko EM et al. The effect of carbohydrate restriction on prostate cancer tumor growth in a castrate mouse xenograft model. Prostate. 2013 Apr;73(5):449-54.
  • Similar survival among mice with prostate cancer with a low-carbohydrate diet (10–20% carbohydrate kcal) compared to a calorie-maintained no-carbohydrate ketogenic diet (0% carbohydrate kcal)28Masko EM, Thomas JA et al. Low-carbohydrate diets and prostate cancer: How low is “low enough”? Cancer Prevention Research (Philadelphia, Pennsylvania). 2010 Sep;3(9):1124-31.

Professional resources

Cancer Strategies Journal

See Glioblastoma multiforme (GBM) and the ketogenic diet

Clinical Pearls, Fall 2013

Keep reading about ketogenic diet

Author

Laura Pole, RN, MSN, OCNS

Senior Clinical Consultant
View profile

Laura Pole is senior clinical consultant for CancerChoices. Laura is an oncology clinical nurse specialist who has been providing integrative oncology clinical care, navigation, consultation, and education services for over 40 years. She is the co-creator and co-coordinator of the Integrative Oncology Navigation Training at Smith Center for Healing and the Arts in Washington, DC. Laura also manages the “Media Watch Cancer News That You Can Use” listserv for Smith Center/Commonweal. In her role as a palliative care educator and consultant, Laura has served as statewide Respecting Choices Faculty for the Virginia POST (Physician Orders for Scope of Treatment) Collaborative as well as provided statewide professional education on palliative and end-of-life care for the Virginia Association for Hospices and Palliative Care.

For CancerChoices, Laura curates content and research, networks with clinical and organizational partners, brings awareness and education of integrative oncology at professional and patient conferences and programs, and translates research into information relevant to the patient experience as well as clinical practice.

Laura sees her work with CancerChoices as a perfect alignment of all her passions, knowledge and skills in integrative oncology care. She is honored to serve you.

Laura Pole, RN, MSN, OCNS Senior Clinical Consultant

Nancy Hepp, MS

Lead Researcher and Program Manager
View profile

Ms. Hepp is a researcher and communicator who has been writing and editing educational content on varied health topics for more than 20 years. She serves as lead researcher, program manager, and writer for CancerChoices. Her graduate work in research and cognitive psychology, her master’s degree in instructional design, and her certificate in web design have all guided her in writing and presenting information for a wide variety of audiences and uses. Nancy’s service as faculty development coordinator in the Department of Family Medicine at Wright State University also provided experience in medical research, plus insights into medical education and medical care from the professional’s perspective.

Nancy Hepp, MS Lead Researcher and Program Manager

Reviewers

Lise Alschuler, ND, FABNO

Naturopathis oncologist and CancerChoices advisor
View profile

Dr. Alschuler, ND, FABNO, is a professor of Clinical Medicine at the University of Arizona where she is the associate director of the Fellowship in Integrative Medicine at the Andrew Weil Center for Integrative Medicine. She received her undergraduate degree from Brown University and completed her naturopathic medical training at Bastyr University where she also completed her residency in general naturopathic medicine. She is board certified in naturopathic oncology and maintains a clinical practice out of Naturopathic Specialists, LLC. Dr. Alschuler co-hosts a podcast, Five To Thrive Live!. She is co-author of Definitive Guide to Cancer, now in its 3rd edition, and Definitive Guide to Thriving After Cancer.

Lise Alschuler, ND, FABNO Naturopathis oncologist and CancerChoices advisor

Last update: November 30, 2022

Last full literature review: September 2021

CancerChoices provides information about integrative in cancer care, a patient-centered approach combining the best of conventional care, self care and evidence-informed complementary care in an integrated plan cancer care. We review complementaryin cancer care, complementary care involves the use of therapies intended to enhance or add to standard conventional treatments; examples include supplements, mind-body approaches such as yoga or psychosocial therapy, and acupuncture therapies and self-care lifestyle actions and behaviors that may impact cancer outcomes; examples include eating health-promoting foods, limiting alcohol, increasing physical activity, and managing stress practices to help patients and professionals explore and integrate the best combination of conventionalthe cancer care offered by conventionally trained physicians and most hospitals; examples are chemotherapy, surgery, and radiotherapy and complementary therapies and practices for each person.

Our staff have no financial conflicts of interest to declare. We receive no funds from any manufacturers or retailers gaining financial profit by promoting or discouraging therapies mentioned on this site.

Health professional comment

We invite health professionals to contribute expertise or send us questions.

"*" indicates required fields

Please share your thoughts about content on the CancerChoices website. If you have a correction for us to consider, or additional information to add, please include references and links if possible.

References[+]